All is well between Eli Lilly and the FDA after the agency’s Office of Prescription Drug Promotion (OPDP) admonished the drugmaker for not submitting two direct-to-consumer TV advertisements for its migraine drug Emgality (galcanezumab) to FDA for consideration before the ads aired.
Source: Drug Industry Daily